Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER vs AMINOSYN 10% (PH6)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Electrolyte and amino acid supplementation to maintain or restore fluid balance, provide calories from dextrose, and supply essential amino acids for protein synthesis; calcium and other electrolytes support physiological functions.
Aminosyn 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, helping to maintain nitrogen balance and support tissue repair and growth in patients unable to receive adequate nutrition enterally.
Provision of calories, amino acids, and electrolytes for parenteral nutrition in patients requiring central venous administration,Short-term maintenance of nitrogen balance in patients with inadequate oral intake
Parenteral nutrition for prevention of nitrogen loss or treatment of negative nitrogen balance in patients where oral or enteral nutrition is impossible or insufficient
Intravenous infusion at a rate determined by clinical condition and metabolic requirements. Typical adult initial rate: 100 m L/hr, adjusted based on glucose tolerance and fluid status.
Intravenous infusion: 1 to 1.5 g/kg/day (equivalent to 10 to 15 m L/kg/day of 10% solution) for adult patients with normal nutritional status; adjust based on metabolic needs.
Not applicable as a single entity; amino acids have half-lives ranging from minutes to hours depending on individual amino acid metabolism. Dextrose has a half-life of about 1-2 hours in fasting state, but this formulation is for continuous infusion, so elimination is constant.
The terminal elimination half-life of individual amino acids varies (1–4 hours) depending on metabolic demand and renal function. For the amino acid mixture, the effective half-life is approximately 2 hours in patients with normal renal function. This short half-life necessitates continuous or frequent infusion to maintain stable plasma levels.
Dextrose is metabolized via glycolysis and oxidative pathways; amino acids are catabolized in the liver and tissues; electrolytes are handled by the kidneys.
Amino acids are metabolized through deamination, transamination, and decarboxylation pathways, primarily in the liver, with nitrogen converted to urea via the urea cycle and carbon skeletons entering the Krebs cycle.
Renal excretion of amino acids and dextrose metabolites; no significant biliary or fecal elimination. Unused amino acids are deaminated and excreted as urea in urine (approximately 80-90% of nitrogen load). Electrolytes are excreted renally.
Amino acids from Aminosyn 10% are primarily utilized for protein synthesis and metabolic processes. Excess nitrogen is eliminated via the kidneys as urea (renal elimination accounts for >90% of nitrogen excretion). Minimal biliary/fecal elimination (<5%) occurs via unabsorbed amino acids in patients with malabsorption. In renal impairment, elimination is reduced.
Amino acids and electrolytes are minimally protein-bound (<5%); no specific binding proteins. Dextrose does not bind to proteins.
Amino acids exhibit low protein binding (<10%) to plasma proteins (primarily albumin). High-affinity binding is negligible; most amino acids circulate freely.
Amino acids distribute into total body water (approximately 0.6 L/kg). Dextrose distributes into extracellular fluid (approximately 0.2 L/kg). Electrolytes distribute according to their body compartments (e.g., sodium 0.15 L/kg, potassium 0.4 L/kg).
Volume of distribution (Vd) for amino acids in Aminosyn 10% ranges from 0.3–0.5 L/kg, approximating total body water. This reflects extensive distribution into extracellular and intracellular compartments.
Intravenous only; 100% bioavailability via IV infusion. Not administered via other routes.
Bioavailability is 100% when administered intravenously. Not applicable for oral, intramuscular, or other routes; Aminosyn 10% is for IV use only.
Contraindicated in patients with severe renal impairment (e GFR < 30 m L/min/1.73m²) due to risk of electrolyte and fluid overload. For mild to moderate impairment (e GFR 30-89 m L/min/1.73m²), monitor serum potassium, calcium, phosphorus, and magnesium; reduce infusion rate as needed.
For GFR 30-59 m L/min: reduce dose to 0.8-1.0 g/kg/day. For GFR 15-29 m L/min: 0.6-0.8 g/kg/day. For GFR <15 m L/min or dialysis: 0.5-0.6 g/kg/day; monitor for azotemia.
Use with caution in hepatic impairment; no specific Child-Pugh based dosing. Monitor for signs of hyperammonemia and fluid overload. Avoid in severe hepatic encephalopathy.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 30-50% and use a formulation with higher branched-chain amino acids. Child-Pugh Class C: avoid or use with extreme caution, adjust based on ammonia levels.
Weight-based dosing individualized per metabolic and fluid needs. Typical range: 20-40 m L/hr for neonates and infants, adjusted for age and condition. Maximum glucose infusion rate: 12-14 mg/kg/min for neonates.
Infants (0-1 year): 2-3 g/kg/day (20-30 m L/kg/day). Children (1-12 years): 1.5-2.5 g/kg/day (15-25 m L/kg/day). Adolescents: 1-1.5 g/kg/day (10-15 m L/kg/day). Administer as continuous IV infusion.
Use with caution; monitor renal function and fluid balance. Start at lower infusion rates (e.g., 50-75 m L/hr) and titrate slowly due to reduced renal clearance and higher risk of electrolyte disturbances.
Initiate at lower end of dosing range (0.8-1 g/kg/day) due to reduced renal function and increased risk of fluid overload; monitor serum electrolytes and renal function closely.
Not for use in patients with severe renal impairment, anuria, or known hypersensitivity to any component. Risk of fluid overload, electrolyte imbalances, and hyperglycemia. Must be administered under medical supervision with monitoring of electrolytes, blood glucose, and acid-base status.
None
Use caution in patients with renal insufficiency (risk of electrolyte abnormalities), hepatic impairment (risk of hyperammonemia), and diabetes mellitus (risk of hyperglycemia). Monitor for signs of phlebitis or extravasation. Avoid rapid infusion to prevent hyperglycemia and fluid overload.
Risk of hyperammonemia, especially in patients with hepatic impairment,Risk of metabolic acidosis,Risk of fluid overload and electrolyte imbalances,Monitor for signs of infection or phlebitis at infusion site,Use with caution in patients with renal insufficiency as may worsen azotemia
Hypersensitivity to any component,Clinically significant hyperglycemia,Severe renal impairment or anuria,Uncompensated heart failure,Pulmonary edema,Health status where intravenous fluid administration is contraindicated
Hypersensitivity to any component,Inborn errors of amino acid metabolism (e.g., maple syrup urine disease),Severe hepatic failure with encephalopathy,Severe azotemia or anuria
No direct food interactions as this is an intravenous product. However, oral intake is typically restricted during TPN therapy. Patients receiving TPN may require monitoring of blood glucose and electrolytes if transitioning to oral feeds. Avoid concurrent administration of alcohol due to risk of hypoglycemia.
No specific food interactions. However, since this is used in parenteral nutrition, oral intake may be contraindicated. Adjustments may be needed if transitioning to oral feeding.
No teratogenic risk attributed to components at therapeutic doses; dextrose and electrolytes are essential nutrients. Fetal risks are primarily from maternal metabolic disturbances (e.g., hyperglycemia, electrolyte imbalances) which may cause fetal macrosomia, neonatal hypoglycemia, or electrolyte abnormalities if improperly managed. No specific trimester risk increase identified beyond maternal condition.
Amino acids are essential nutrients; no teratogenic risk is known when used at recommended doses. However, safety during pregnancy has not been established through controlled studies. First trimester: No evidence of fetal harm. Second/third trimester: Use only if clearly needed; monitor maternal and fetal status.
Components (dextrose, electrolytes) are normally present in breast milk and considered compatible with breastfeeding. No M/P ratio available; risk to infant is low when maternal levels are maintained within physiological ranges.
Excretion of amino acids into breast milk is not well studied. Considering the endogenous nature of amino acids, risk to infant is likely low if used at recommended doses. M/P ratio not determined.
No specific dose adjustments required; however, glucose infusion rate may need titration to avoid maternal hyperglycemia due to insulin resistance in pregnancy. Electrolyte requirements may increase, especially potassium and calcium; adjust based on frequent monitoring. Volume status should be carefully managed to avoid fluid overload.
No specific dose adjustments required. Pregnancy may alter fluid and electrolyte needs; individualize dosing based on clinical status and laboratory parameters.
This is a high-osmolality (850 m Osm/L) parenteral nutrition solution containing 35% dextrose, amino acids, and electrolytes including calcium. MUST be administered via central venous line to prevent thrombophlebitis. Contains sulfite (≤0.3 m Eq/L) as sodium metabisulfite; contraindicated in patients with known sulfite hypersensitivity (e.g., asthmatics). The calcium concentration (approx 4.7 m Eq/L) is low; monitor ionized calcium in critically ill patients. Do not add phosphate to this solution as it may precipitate calcium phosphate. Use within 24 hours of spiking the bag; discard any unused portion. Incompatible with lipid emulsions; administer separately via Y-site with compatible fluids.
Aminosyn 10% (p H 6) is a crystalline amino acid solution used for parenteral nutrition. Monitor serum electrolytes, BUN, and ammonia levels due to risk of metabolic abnormalities. Adjust infusion rate to avoid hyperglycemia or hypoglycemia. Use with caution in renal or hepatic impairment. Check for compatible additives and avoid mixing with lipids in the same container unless validated.
This medication is a total parenteral nutrition (TPN) solution that provides complete nutrition intravenously.,It contains dextrose (sugar), amino acids (protein), electrolytes, calcium, and sulfites.,Notify your nurse immediately if you experience difficulty breathing, rash, itching, or swelling, especially if you have asthma or sulfite allergy.,You will need a special central venous catheter (large IV in chest or neck) to receive this solution.,Do not eat or drink anything unless instructed; this solution replaces oral nutrition.,Tell your doctor if you have diabetes, kidney problems, or fluid/electrolyte imbalances.
Report any signs of infection at the IV site, such as redness, swelling, or pain.,Inform your healthcare provider if you experience nausea, vomiting, or dizziness.,This solution provides essential nutrients; do not stop treatment without consulting your doctor.,Keep an eye on your blood sugar levels if you have diabetes.,Do not take any other nutritional supplements without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER vs AMINOSYN 10% (PH6), answered by our medical review team.
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by Electrolyte and amino acid supplementation to maintain or restore fluid balance, provide calories from dextrose, and supply essential amino acids for protein synthesis; calcium and other electrolytes support physiological functions.. AMINOSYN 10% (PH6) is a Parenteral Nutrition Solution that works by Aminosyn 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, helping to maintain nitrogen balance and support tissue repair and growth in patients unable to receive adequate nutrition enterally.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER and AMINOSYN 10% (PH6) depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous infusion at a rate determined by clinical condition and metabolic requirements. Typical adult initial rate: 100 m L/hr, adjusted based on glucose tolerance and fluid status.. The standard adult dose of AMINOSYN 10% (PH6) is: Intravenous infusion: 1 to 1.5 g/kg/day (equivalent to 10 to 15 m L/kg/day of 10% solution) for adult patients with normal nutritional status; adjust based on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER and AMINOSYN 10% (PH6) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. No teratogenic risk attributed to components at therapeutic doses; dextrose and electrolytes are essential nutrients. Fetal risks are primarily from maternal metabolic disturbances. AMINOSYN 10% (PH6) is classified as Category C. Amino acids are essential nutrients; no teratogenic risk is known when used at recommended doses. However, safety during pregnancy has not been established through controlled studi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.